Search results
Results from the WOW.Com Content Network
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
An alpha privative or, rarely, [1] privative a (from Latin alpha prīvātīvum, from Ancient Greek α στερητικόν) is the prefix a-or an-(before vowels) that is used in Indo-European languages such as Sanskrit and Greek and in words borrowed therefrom to express negation or absence, for example the English words of Greek origin atypical, anesthetic, and analgesic.
It covers research on all aspects of cancer and cancer-related biomedical sciences and was established in 1941. The editor-in-chief is Chi Van Dang. [1] The journal was established in 1916 as the Journal of Cancer Research, was renamed American Journal of Cancer in 1931, and obtained its current name in 1941.
Journal of Cancer; Journal of Cancer Research and Clinical Oncology; Journal of Cancer Research and Therapeutics; Journal of Carcinogenesis; Journal of Clinical Oncology; Journal of Cytology; Journal of Environmental Science and Health, Part C; Journal of Experimental & Clinical Cancer Research; Journal of Neuro-Oncology; Journal of Surgical ...
Cancers is a peer-reviewed, open access, medical journal published by MDPI covering all fields of oncology. [1] The editor-in-chief is Samuel C. Mok (The University of Texas MD Anderson Cancer Center). The Irish Association for Cancer Research (IACR) and the Signal Transduction Society (STS) are affiliated societies.
Another form of targeted therapy involves the use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body. Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells.
Eftilagimod alpha (INN; [1] development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3 .
The phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (the HUGO-approved official symbol = PIK3CA; HGNC ID, HGNC:8975), also called p110α protein, is a class I PI 3-kinase catalytic subunit. The human p110α protein is encoded by the PIK3CA gene. [5] Its role was uncovered by molecular pathological epidemiology (MPE). [6]